EPS for Onconova Therapeutics, Inc. (ONTX) Expected At $-0.32; Banque Pictet & Cie Sa Cut By $6.98 Million Its U S Silica Hldgs (SLCA) Position

April 16, 2018 - By Hazel Jackson

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Logo

Analysts expect Onconova Therapeutics, Inc. (NASDAQ:ONTX) to report $-0.32 EPS on May, 21.They anticipate $0.91 EPS change or 73.98% from last quarter’s $-1.23 EPS. After having $-0.59 EPS previously, Onconova Therapeutics, Inc.’s analysts see -45.76% EPS growth. The stock decreased 1.20% or $0.0095 during the last trading session, reaching $0.7805. About 68,226 shares traded. Onconova Therapeutics, Inc. (NASDAQ:ONTX) has declined 70.37% since April 16, 2017 and is downtrending. It has underperformed by 81.92% the S&P500.

Banque Pictet & Cie Sa decreased U S Silica Hldgs Inc (SLCA) stake by 47.45% reported in 2017Q4 SEC filing. Banque Pictet & Cie Sa sold 218,060 shares as U S Silica Hldgs Inc (SLCA)’s stock declined 23.14%. The Banque Pictet & Cie Sa holds 241,541 shares with $7.87M value, down from 459,601 last quarter. U S Silica Hldgs Inc now has $2.22 billion valuation. The stock increased 1.09% or $0.3 during the last trading session, reaching $27.51. About 1.26 million shares traded. U.S. Silica Holdings, Inc. (NYSE:SLCA) has declined 43.79% since April 16, 2017 and is downtrending. It has underperformed by 55.34% the S&P500.

Among 2 analysts covering Onconova Therapeutics (NASDAQ:ONTX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Onconova Therapeutics had 14 analyst reports since September 3, 2015 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Monday, October 9. The firm earned “Buy” rating on Tuesday, June 6 by Maxim Group. The stock has “Buy” rating by H.C. Wainwright on Thursday, November 9. Maxim Group maintained Onconova Therapeutics, Inc. (NASDAQ:ONTX) rating on Tuesday, August 15. Maxim Group has “Buy” rating and $600 target. The firm earned “” rating on Thursday, September 3 by H.C. Wainwright. The stock of Onconova Therapeutics, Inc. (NASDAQ:ONTX) has “Hold” rating given on Wednesday, January 31 by Maxim Group. H.C. Wainwright maintained Onconova Therapeutics, Inc. (NASDAQ:ONTX) rating on Friday, March 9. H.C. Wainwright has “Buy” rating and $7.5 target. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, December 19 report. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, January 4. H.C. Wainwright maintained it with “Buy” rating and $7.5000 target in Monday, March 26 report.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company has market cap of $14.79 million. The company's clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes ; Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.

Banque Pictet & Cie Sa increased Colgate Palmolive Co (NYSE:CL) stake by 425,225 shares to 1.91 million valued at $143.95 million in 2017Q4. It also upped Verizon Communications Inc (NYSE:VZ) stake by 13,500 shares and now owns 35,900 shares. Ishares Tr (IYR) was raised too.

Analysts await U.S. Silica Holdings, Inc. (NYSE:SLCA) to report earnings on April, 23. They expect $0.50 earnings per share, up 455.56% or $0.41 from last year’s $0.09 per share. SLCA’s profit will be $40.35M for 13.76 P/E if the $0.50 EPS becomes a reality. After $0.51 actual earnings per share reported by U.S. Silica Holdings, Inc. for the previous quarter, Wall Street now forecasts -1.96% negative EPS growth.

Among 28 analysts covering U.S. Silica (NYSE:SLCA), 22 have Buy rating, 1 Sell and 5 Hold. Therefore 79% are positive. U.S. Silica had 104 analyst reports since July 30, 2015 according to SRatingsIntel. Credit Suisse maintained the shares of SLCA in report on Thursday, February 22 with “Outperform” rating. The rating was maintained by Morgan Stanley with “Overweight” on Thursday, May 26. DA Davidson downgraded U.S. Silica Holdings, Inc. (NYSE:SLCA) rating on Monday, December 12. DA Davidson has “Underperform” rating and $42 target. Piper Jaffray maintained it with “Buy” rating and $3100 target in Thursday, April 5 report. The rating was initiated by FBR Capital with “Buy” on Wednesday, December 6. Morgan Stanley maintained U.S. Silica Holdings, Inc. (NYSE:SLCA) rating on Thursday, April 28. Morgan Stanley has “Overweight” rating and $33 target. The stock of U.S. Silica Holdings, Inc. (NYSE:SLCA) has “Buy” rating given on Monday, December 7 by DA Davidson. Jefferies downgraded it to “Underperform” rating and $14 target in Friday, September 11 report. Jefferies maintained the stock with “Buy” rating in Tuesday, July 4 report. The stock of U.S. Silica Holdings, Inc. (NYSE:SLCA) has “Outperform” rating given on Thursday, July 30 by RBC Capital Markets.

U.S. Silica Holdings, Inc. (NYSE:SLCA) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>